BioLife Solutions, Inc. (BLFS) Sets New 52-Week High at $4.85
BioLife Solutions, Inc. (NASDAQ:BLFS) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $4.85 and last traded at $4.82, with a volume of 296,688 shares. The stock had previously closed at $4.68.
Several equities research analysts have recently issued reports on the stock. Maxim Group set a $6.00 price objective on shares of BioLife Solutions and gave the stock a “buy” rating in a research note on Friday, August 11th. Janney Montgomery Scott upgraded shares of BioLife Solutions from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $2.62 to $5.00 in a research note on Wednesday, July 5th.
The company’s market cap is $64.16 million. The stock has a 50 day moving average of $3.50 and a 200 day moving average of $2.47.
BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, August 10th. The medical equipment provider reported ($0.06) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06). BioLife Solutions had a negative return on equity of 64.98% and a negative net margin of 63.71%. The business had revenue of $2.56 million for the quarter, compared to analysts’ expectations of $2.40 million. Analysts expect that BioLife Solutions, Inc. will post ($0.24) EPS for the current year.
BioLife Solutions Company Profile
BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.